On April 2, 2018, the board of directors of Kindred Biosciences, Inc. appointed Ernest Mario to serve as a Class I director of the company, effective as of April 2, 2018, for a term expiring at 2020 annual meeting of stockholders. As a result of Dr. Mario's appointment, the authorized size of the Board was increased to five members. Dr. Mario is an independent director in accordance with the listing requirements of The NASDAQ Stock Market. Dr. Mario previously served as a member of the company's Board from February 15, 2013 until May 23, 2016. Dr. Mario served as Deputy Chairman of Glaxo Holdings plc from 1992 to 1993 and as Chief Executive Officer from 1989 to 1993. From 1993 until 2001, he was Chairman and Chief Executive Officer of ALZA Corporation. From 2003 until 2007, Dr. Mario served as Chairman and Chief Executive Officer of Reliant Pharmaceuticals. He currently is Chairman of Soleno Therapeutics Inc. He is also a Venture Partner with Pappas Ventures and serves on a number of corporate boards, including the following public companies: Soleno Therapeutics Inc., Celgene Corporation, Chimerix Inc., Eyenovia Inc. and Tonix Pharmaceuticals Holding Corporation.